Medtronic Completes PMA Application For Symplicity Spyral Hypertension Device
The six-month results from SPYRAL HTN ON MED trial of Medtronic’s Symplicity Spyral renal denervation system did not meet its primary endpoint, but the company and analysts expect the FDA will still approve Symplicity Spyral as the first renal denervation system available in the US to treat uncontrolled hypertension.
You may also be interested in...
The late-breaking clinical trial presentations at this year’s Transcatheter Cardiovascular Therapeutics conference in Boston included new results from trials of three different minimally invasive approaches to treat uncontrolled hypertension.
Minimizing the variability in patient attributes and procedural techniques will be crucial to future renal denervation trials having a chance at success, experts suggested last month at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C.
CMR Surgical will collaborate with Johnson & Johnson/Ethicon to expand access to its Versius robotic surgery system.